Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
R. Jacob Vogelstein
AddedMar 31, 2024
UpdatedMay 31, 2026
R. Jacob Vogelstein

R. Jacob Vogelstein

Co-Founder, Catalio Capital Management

CrunchbaseLinkedIn

R. Jacob Vogelstein's Career

Catalio Capital Management
Catalio Capital Management

New York City, NY, US

Co-Founder
Metabolon
Metabolon

Durham, NC, US

Board Member· Board
Iambic Therapeutics
Iambic Therapeutics

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

R. Jacob Vogelstein's Career

Catalio Capital Management
Catalio Capital Management
Investment FirmInvestment Firm442020New York City, NY, US
Co-Founder

Leadership at Catalio Capital Management

Edward J. MathiasEdward J. MathiasBoard Member
George PetrocheilosGeorge PetrocheilosCo-Founder

Similar to Catalio Capital Management

CapitalXCapitalXSan Francisco, CA, USest. 2020CapitalXSan Francisco, CA, US · est. 2020

CapitalX, an early-stage venture capital firm, offers high-conviction investments in pre-seed/seed rounds.

Investment Firm9
Triangle Peak PartnersTriangle Peak PartnersPalo Alto, CA, USest. 2008Triangle Peak PartnersPalo Alto, CA, US · est. 2008

Triangle Peak Partners is a venture capital firm backing growth-stage technology, clean tech, and energy companies.

Investment Firm30
Catalysta VenturesCatalysta VenturesDurham, NC, USest. 2010Catalysta VenturesDurham, NC, US · est. 2010

Hatteras Venture Partners: A US-based venture capital firm investing in healthcare and biopharmaceutical sectors.

Investment Firm8
Bold Capital PartnersBold Capital PartnersSanta Monica, CA, USest. 2015Bold Capital PartnersSanta Monica, CA, US · est. 2015

Bold Capital Partners, co-founded by Peter Diamandis, is a venture capital firm investing in tech companies.

Investment Firm17
Metabolon
Metabolon
Public$199.7M3022000Durham, NC, US
Board Member· Board

Leadership at Metabolon

Christopher KerseyChristopher KerseyBoard Member
John RyalsJohn RyalsBoard Member
John OxaalJohn OxaalBoard Member
Paul SchimmelPaul SchimmelCo-Founder
Tom CaskeyTom CaskeyBoard Member
Jeff ClarkJeff ClarkBoard Member

Similar to Metabolon

Molecular BiometricsMolecular BiometricsNorwood, MA, USHealth Diagnosticsest. 2005Molecular BiometricsNorwood, MA, US · est. 2005

Molecular Biometrics develops non-invasive methods using metabolomic technologies for health evaluation.

Series B · $24.5M30
Panome BioPanome BioSt. Louis, MO, USBiomarker Discoveryest. 2022Panome BioSt. Louis, MO, US · est. 2022

Panome Bio: A next-gen biomarker discovery platform offering comprehensive metabolomics solutions, founded in 2022.

Series A · $6M13
Phenomix SciencesPhenomix SciencesRochester, MN, USBiotechest. 2017Phenomix SciencesRochester, MN, US · est. 2017

Phenomix Sciences: A biotech firm excelling in life science, metabolomics, and genomics.

Pre-Seed · $3.2M5
QuanterixQuanterixBillerica, MA, USBiomarker Analysisest. 2007QuanterixBillerica, MA, US · est. 2007

Quanterix: Advancing precision health science through digitized biomarker analysis in Lexington, US.

Public · $533.3M125
Iambic Therapeutics
Iambic Therapeutics
Series B$153M752019San Diego, CA, US
Board Member· Board

Leadership at Iambic Therapeutics

Fred ManbyFred ManbyCo-Founder
Thomas MillerThomas MillerBoard Member

Similar to Iambic Therapeutics

Seismic TherapeuticSeismic TherapeuticWatertown, MA, USBiologics, Drug Discoveryest. 2020Seismic TherapeuticWatertown, MA, US · est. 2020

Seismic Therapeutic: A biotech firm using machine learning to expedite immunology drug development.

Series B · $222M58
Athos TherapeuticsAthos TherapeuticsTorrance, CA, USTherapeuticsest. 2019Athos TherapeuticsTorrance, CA, US · est. 2019

Athos Therapeutics: Pioneering AI-based precision treatments for autoimmune diseases and cancer.

Series A · $19.3M15
Pathos AIPathos AIChicago, IL, USDrug Discoveryest. 2020Pathos AIChicago, IL, US · est. 2020

Pathos: AI and big data-driven platform streamlining end-to-end drug discovery and development.

Series B · $20M3
DeepCureDeepCureBoston, MA, USDrug Discoveryest. 2018DeepCureBoston, MA, US · est. 2018

DeepCure: Accelerating affordable AI-powered drug discovery for better, faster results.

Series A · $40M39

R. Jacob Vogelstein's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to R. Jacob Vogelstein

Stephen R ForrestStephen R ForrestBoard Member · Universal DisplayJoel DawsonJoel DawsonCo-Founder · Eta WirelessVincent HarrisVincent HarrisBoard Member · MetamagneticsDavid BlaauwDavid BlaauwCo-Founder · CubeWorksShanhui FanShanhui FanCo-Founder · SkyCool SystemsZhihua QuZhihua QuBoard Member · University of Central Florida